Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91% Market Closed
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

Egetis Therapeutics AB (publ)
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Egetis Therapeutics AB (publ)
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Egetis Therapeutics AB (publ)
STO:EGTX
Long-Term Investments
kr800k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Long-Term Investments
kr28.1m
CAGR 3-Years
796%
CAGR 5-Years
266%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Long-Term Investments
kr217k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Long-Term Investments
kr54m
CAGR 3-Years
20%
CAGR 5-Years
11%
CAGR 10-Years
24%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Long-Term Investments
kr175m
CAGR 3-Years
-3%
CAGR 5-Years
-17%
CAGR 10-Years
10%
BioArctic AB
STO:BIOA B
Long-Term Investments
kr1.6m
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Egetis Therapeutics AB (publ)
Glance View

Market Cap
2.4B SEK
Industry
Biotechnology

Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

EGTX Intrinsic Value
9.63 SEK
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Egetis Therapeutics AB (publ)'s Long-Term Investments?
Long-Term Investments
800k SEK

Based on the financial report for Dec 31, 2023, Egetis Therapeutics AB (publ)'s Long-Term Investments amounts to 800k SEK.

What is Egetis Therapeutics AB (publ)'s Long-Term Investments growth rate?
Long-Term Investments CAGR 1Y
0%

Over the last year, the Long-Term Investments growth was 0%.

Back to Top